共 58 条
[1]
Haase D(2007)New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 4385-4395
[2]
Germing U(2008)Cytogenetic features in myelodysplastic syndromes Ann Hematol 87 515-526
[3]
Schanz J(2005)Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity Mayo Clin Proc 80 681-698
[4]
Pfeilstocker M(2006)Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456-1465
[5]
Nosslinger T(2008)Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing Cancer Genet Cytogenet 187 101-111
[6]
Hildebrandt B(2008)Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes Ann Hematol 87 345-352
[7]
Kundgen A(2007)Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q) MDS patients with unexpected responses Ann Hematol 86 133-137
[8]
Lubbert M(undefined)undefined undefined undefined undefined-undefined
[9]
Kunzmann R(undefined)undefined undefined undefined undefined-undefined
[10]
Giagounidis AA(undefined)undefined undefined undefined undefined-undefined